Pharmacy Services
Valdecoxib (Bextra) Associated with Hypersensitivity Reactions
December 13, 2002
Pfizer has changed the labeling for Bextra (valdecoxib) to include warnings about the potential for hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis. Additional information is available at the following links:
- MedWatch Alert:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154472.htm - Letter to HealthCare Professionals:
http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM170876.pdf
Updated
December 13, 2002; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT.
Social Media
Copyright © 2013 University of Utah Health Care